President Donald Trump’s nominee for Surgeon General, Dr. Nicole Saphier, has disclosed a portfolio of investments in major consumer and technology companies and agreed to divest from the majority of those holdings if confirmed for the role.
In an ethics agreement released Thursday, Saphier outlined a plan to sell off stakes in more than 200 companies within 90 days of her confirmation. The divestiture list includes major tobacco manufacturers, fast-food chains, and beverage companies. Specifically, she is required to sell holdings in Altria Group Inc. (NYSE: MO), British American Tobacco PLC (NYSE: BTI), and Philip Morris International Inc. (NYSE: PM).
The agreement also mandates the sale of positions in the food and beverage sector. Saphier will divest from McDonald’s Corp. (NYSE: MCD), Coca-Cola Co. (NYSE: KO), PepsiCo Inc. (NASDAQ: PEP), Monster Beverage Corp. (NASDAQ: MNST), Starbucks Corp. (NASDAQ: SBUX), and Yum Brands Inc. (NYSE: YUM).
Additionally, the ethics filing indicates that Saphier will sell her stakes in major pharmaceutical and healthcare companies, including Eli Lilly & Co. (NYSE: LLY), Merck & Co. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), UnitedHealth Group Inc. (NYSE: UNH), and CVS Health Corp. (NYSE: CVS). She will also divest from technology giants Apple Inc. (NASDAQ: AAPL), Nvidia Corp. (NASDAQ: NVDA), Meta Platforms Inc. (NASDAQ: META), and Amazon.com Inc. (NASDAQ: AMZN), as well as energy companies Exxon Mobil Corp. (NYSE: XOM) and Chevron Corp. (NYSE: CVX).
A smaller group of holdings, including Johnson & Johnson (NYSE: JNJ), JPMorgan Chase & Co. (NYSE: JPM), Microsoft Corp. (NASDAQ: MSFT), and Pfizer Inc. (NYSE: PFE), will be subject to partial divestment because some of those positions are held through two LLCs.
Saphier, a radiologist and former Fox News contributor, currently serves as an associate attending physician and director of breast imaging at Memorial Sloan Kettering Cancer Center in New York. Her confirmation hearing before the Senate is scheduled for Sept. 16.
